Last reviewed · How we verify
emollient cream — Competitive Intelligence Brief
marketed
Topical emollient
Dermatology
Small molecule
Live · refreshed every 30 min
Target snapshot
emollient cream (emollient cream) — Children's Hospital Medical Center, Cincinnati. An emollient cream hydrates and softens the skin by forming an occlusive barrier that reduces transepidermal water loss.
Comparator set (3 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| emollient cream TARGET | emollient cream | Children's Hospital Medical Center, Cincinnati | marketed | Topical emollient | ||
| Aqueous cream | Aqueous cream | The University of Hong Kong | marketed | Topical emollient | ||
| Salkera Emollient Foam | Salkera Emollient Foam | Wright State University | marketed | Topical emollient | ||
| Colloidal Oatmeal Cream | Colloidal Oatmeal Cream | Johnson & Johnson Consumer and Personal Products Worldwide | marketed | Topical emollient and skin protectant |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Topical emollient class)
- Children's Hospital Medical Center, Cincinnati · 1 drug in this class
- The University of Hong Kong · 1 drug in this class
- Wright State University · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- emollient cream CI watch — RSS
- emollient cream CI watch — Atom
- emollient cream CI watch — JSON
- emollient cream alone — RSS
- Whole Topical emollient class — RSS
Cite this brief
Drug Landscape (2026). emollient cream — Competitive Intelligence Brief. https://druglandscape.com/ci/emollient-cream. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab